PRESS RELEASE published on 02/27/2025 at 08:57, 1 year 2 months ago Informations privilégiées / Communiqué sur comptes, résultats GenSight Biologics publie ses résultats financiers estimés pour l'année 2024. L'entreprise prolonge son horizon de trésorerie jusqu'à avril 2025 grâce à une gestion rigoureuse et au Crédit d'Impôt Recherche Résultats Financiers Trésorerie GenSight Biologics Crédit D'Impôt Recherche AAC
PRESS RELEASE published on 02/27/2025 at 08:57, 1 year 2 months ago Inside Information / News release on accounts, results GenSight Biologics reports estimated full-year 2024 consolidated financial results. Cash runway extended to early April 2025. Resumption of Compassionate Access Program expected in April 2025 Financial Results 2024 GenSight Biologics Cash Runway Compassionate Access Program
BRIEF published on 02/12/2025 at 07:35, 1 year 2 months ago GenSight Biologics Reports Positive Five-Year Outcomes for LUMEVOQ® Gene Therapy Gene Therapy LUMEVOQ® Visual Acuity Safety Profile REFLECT Study
BRIEF published on 02/12/2025 at 07:35, 1 year 2 months ago GenSight Biologics annonce des résultats positifs sur cinq ans pour la thérapie génique LUMEVOQ® Thérapie Génique LUMEVOQ® Acuité Visuelle Profil De Sécurité Étude REFLECT
PRESS RELEASE published on 02/12/2025 at 07:30, 1 year 2 months ago Inside Information / Other news releases GenSight Biologics reports 5-year efficacy and safety results for LUMEVOQ® gene therapy in REFLECT study with sustained visual improvement and favorable safety profile Gene Therapy GenSight Biologics LUMEVOQ Visual Acuity REFLECT Study
PRESS RELEASE published on 02/12/2025 at 07:30, 1 year 2 months ago Informations privilégiées / Autres communiqués GenSight Biologics annonce les résultats à 5 ans de la thérapie génique LUMEVOQ® pour la NOHL, confirmant l'efficacité durable et le profil de sécurité favorable Sécurité Efficacité Thérapie Génique GenSight Biologics LUMEVOQ
BRIEF published on 01/23/2025 at 18:50, 1 year 3 months ago GenSight Biologics : Bilan Financier et Perspectives GenSight Biologics LUMEVOQ® Augmentations De Capital Accès Compassionnel Trésorerie 2024
BRIEF published on 01/23/2025 at 18:50, 1 year 3 months ago GenSight Biologics: Financial Report and Outlook GenSight Biologics Capital Increases LUMEVOQ® Compassionate Access Treasury 2024
PRESS RELEASE published on 01/23/2025 at 18:45, 1 year 3 months ago Informations privilégiées / Communiqué sur comptes, résultats GenSight Biologics publie sa situation financière 2024 et donne des mises à jour sur ses activités, y compris le financement et la progression réglementaire de LUMEVOQ. La trésorerie s'élève à 2,5M€ à fin 2024 Financement Trésorerie Situation Financière GenSight Biologics LUMEVOQ
PRESS RELEASE published on 01/23/2025 at 18:45, 1 year 3 months ago Inside Information / News release on accounts, results GenSight Biologics reports end-of-year cash position and provides business update, including successful capital increases and ongoing review of LUMEVOQ dossier Business Update Cash Position GenSight Biologics Capital Increases LUMEVOQ Dossier
Published on 05/09/2026 at 01:30, 18 hours 6 minutes ago Star Copper Announces Agreement with Zimtu Capital Corp.
Published on 05/09/2026 at 00:00, 19 hours 36 minutes ago Onco-Innovations Progresses Toward IND Preparation as Nucro-Technics Commences Bioanalysis for PNKP Inhibitor Technology
Published on 05/09/2026 at 19:05, 31 minutes ago LONGi EcoLife Series Module Top TaiyangNews Global Ranking, Ushering in the "25%+" Era of Photovoltaic Efficiency
Published on 05/08/2026 at 20:38, 22 hours 58 minutes ago EQS-Adhoc: thyssenkrupp nucera AG & Co. KGaA: Preliminary Figures for Q2/6M 2025/26; Order Intake Above Expectations and Previous Year ; Sales and Earnings below Market Expectations
Published on 05/08/2026 at 19:12, 1 day ago EQS-Adhoc: Viromed Medical AG missed revenue forecast for 2025 financial year, but continued to grow significantly and achieved a positive result; revised forecast for 2026
Published on 05/08/2026 at 19:02, 1 day ago Metall Zug – Annual General Meeting of Shareholders approves all proposals
Published on 05/07/2026 at 19:15, 2 days ago 2026 Annual General Meeting: approval of all resolutions submitted to the Meeting
Published on 05/07/2026 at 19:15, 2 days ago Assemblée Générale annuelle 2026 : approbation de l’ensemble des résolutions soumises au vote
Published on 05/07/2026 at 19:06, 2 days ago Disclosure of Share Capital and Voting Rights as of April 30, 2026
Published on 05/07/2026 at 19:06, 2 days ago Déclaration du nombre d’actions et droits de vote au 30 avril 2026
Published on 05/07/2026 at 19:00, 2 days ago ALTAREIT - INFORMATION RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
